TVM Capital All News

[09.11.2009] EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application for Review

Mon, 09 Nov 2009 16:36:00 GMT

Marketing Application Also Accepted in Israel TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene(R) (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada's performance target for the completion of review and a decision is...

[09.11.2009] Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration

Mon, 09 Nov 2009 16:35:00 GMT

- Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties - Hamburg, Germany - 9 November 2009: Evotec AG (Frankfurt Stock Exchange: EVT; TecDAX, NASDAQ: EVTC) today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. The collaboration was initiated in August 2004 and has been extended on two previous occasions. At the same time, based on the success to date in the areas of...

[09.11.2009] Scientists at TU Braunschweig and DeveloGen AG receive Phoenix Science Award 2009 for a publication in the field of beta cell regeneration

Mon, 09 Nov 2009 16:32:00 GMT

Goettingen, Germany � Nov 9th, 2009: DeveloGen AG, a biotechnology company focused on the discovery and development of novel therapies for diabetes and other metabolic and endocrine disorders announced today that a team of scientist who published an article in the Journal of Medicinal Chemistry in the field of beta cell regeneration was awarded the renowned Phoenix Science Award 2009 in the category pharmaceutical chemistry. The award is endowed with 10.000 Euro. The team of scientists from...

[09.11.2009] Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV

Mon, 09 Nov 2009 16:30:00 GMT

Concert Earns $12 Million Milestone from GlaxoSmithKline CTP-518 has Potential as Unboosted HIV Protease Inhibitor November 9 , 2009 Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the...

[06.11.2009] EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing

Fri, 06 Nov 2009 16:37:00 GMT

TARRYTOWN, N.Y., Nov 06, 2009 (BUSINESS WIRE) -- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has appointed Bernard R. Tyrrell as the Company's Senior Vice President, Sales and Marketing, a newly created position. Mr. Tyrrell joins EpiCept with a wealth of experience in pharmaceutical marketing and business development, both in the U.S. and internationally. Most recently, he led the Oncology Division of Otsuka America Pharmaceutical, Inc....

[04.11.2009] Netviewer Web conferences are climate neutral

Wed, 04 Nov 2009 17:54:00 GMT

Karlsruhe, 03.11.09 - German-based provider of Web conferencing solutions offsets its computing centers� CO2-emissions. Netviewer AG of Germany, Europe�s leading provider of Web conferencing solutions, has found a way to make online meetings and collaboration climate neutral. In cooperation with the non-profit organization PrimaKlima weltweit e.V. (GreatClimate worldwide) the company is reforesting 5 hectares of rain forest in Mexico in order to compensate for the CO2 emitted by its computing...

[02.11.2009] NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic

Mon, 02 Nov 2009 19:21:00 GMT

Stem Cell Mobilizing Spiegelmer� NOX-A12 Berlin, Germany, November 02, 2009 � NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer� technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer� NOX-A12. NOX-A12 is NOXXON�s second drug candidate entering the clinical stage of development within only five months. The Phase I program is currently...

[02.11.2009] Probiodrug Closes Series B Financing Round exceeding EUR 36 Million (US$54 Million)

Mon, 02 Nov 2009 08:43:00 GMT

Company wins BB Biotech and Edmond de Rothschild Investment Partners as co - lead investors, joined by LSP Life Science Partners , Biogen Idec New Ventures and existing investors Halle/Saale, November 2nd, 2009 -- Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimers disease, today announced the successful closing of a Series B financing round. The total round...

[29.10.2009] Concert Pharmaceuticals� Roger Tung Awarded 2009 Mass High Tech All Star Award

Thu, 29 Oct 2009 13:18:00 GMT

October 29 , 2009 Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry. The annual All Star awards honor pioneers and leaders across several business and technology sectors in New England. This year�s honorees will be profiled in a special supplement in the November 4 edition of Mass High Tech: The Journal of New England...

[28.10.2009] Definiens Joins Digital Pathology Association

Wed, 28 Oct 2009 13:06:00 GMT

Image Analysis Company Is Committed to Open Standards for Digital Pathology Munich, Germany and Parsippany, New Jersey�October 28, 2009 � Definiens, the number one Enterprise Image Intelligence� company, today announced that it has joined the Digital Pathology Association (DPA), a non-profit organization committed to the advancement of digital pathology applications in healthcare. As a sponsor of the association, Definiens�s support will help to advance the DPA�s goal of supporting digital...